The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Someone should know something from https://mananos.com/ on LinkedIn or https://efrac.net/ no social media for them ๐ฆ, & https://twitter.com/InvestorMeetCo/status/1695065517009059857
From 43 min Regret, https://www.youtube.com/watch?v=Uh1HnB_WXLA
Gujarat Gas Ltd has increased the industrial gas price, this was the second price hike by Gujarat Gas in a month. http://tinyurl.com/4ejtuyvu
Like your style ๐
https://tinyurl.com/44jpb9wz
gla
Could clx001 be still born when ready? Charles Chen: โMembrane-active peptides have been known to have off-target toxicity concerns,โ he says. Chemistry World
Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. We suggest that stringent genetic validation of the mechanism of action of cancer drugs in the preclinical setting may decrease the number of therapies tested in human patients that fail to provide any clinical benefit. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717492/
Oilmax Energy Founder Says Strong Potential Seen In Discovered Small Fields in Gujarat State & Assam
https://www.bqprime.com/bq-blue-exclusive/oilmax-energy-founder-says-strong-potential-seen-in-discovered-small-fields
Valirx Subsidiaries webpage, proudly displays this after 9 (nine) bl00dy years: SPV model
" ValiSeek Limited is an early example of our SPV model.
ValiSeek is ValiRx's Joint Venture Company, formed with Tangent Reprofiling Limited (a SEEK group company) in 2014 with the purpose of rapidly progressing VAL401 through development. ValiRx currently holds 55% of ValiSeek.
VAL401 is in development for Pancreatic ductal adenocarcinoma and has now successfully completed a pilot Phase 2 clinical trial and ValiSeek is seeking external partners to continue clinical development. Read more about VAL401, its published research and patents here. "
End result of evaluations is 50/50, discovering a drug may mean billions, or waste of time & money saved. Need many evaluations in hand to work on to hit the jackpot in shortest possible time frame. Wonder if the biobank has any tnbc human tissue already.
For fairness, when one time poster exposed who Viera was, people followed him with their money. Shortly after he warned them not to buy shares just because he was invested in here. So far, didnt see The Prof doing the similar. (may missed it)
Make no mistake, everyone is here to make some money by means they can employ.
Are liability until they compensate themselves. How long it will take to compensate itself how many contracts, how much profit margin required. Jason Monteleone`s case studies indicate that profit margin for CRO is btw 30.5 -50%.
Nothing wrong having more collaborations & one-stop company for many studies unless if they have already built graveyard for collaborations & IP in the past. This company holds an IP for HIV vaccine. Old habits are hard to dies. The company had been collecting items from skips of failed biotech companies, to make something out of them, so far there is not much to show.
Valirx had to make an announcement due to investors pressure for the outcome of val301 from Japanese company after 30 moths of materials shipped. They are playing for longer game, buying time from trapped investors.
Clx001, brand spanking new membrane active peptide, needs to be worked on 24/7 nonstop to have it ready. First page of Valirx website states " .............. the rapid translation of innovative science into clinical development." How reliable their evaluations must be seen ASAP, not after min of 15 years noncommercial Val series compound.
Some say valirx is on its way to become Contract Research Organization (CRO), filling the gap and think that with expected future contracts company will be first self sufficient than turning profit yoy.
Patricio Ledesma, Head of Clinical Operations at Sofpromed CRO https://www.sofpromed.com/ , explains briefly how cro contracts valued.
" As far as CROs dedicated to clinical trial management are concerned, for all the regulatory, site management, clinical monitoring, data management, statistics, medical writing, and project management services, this is, those services provided by staff, pricing is calculated considering the amount of work time to be dedicated (hours) by each member. Based on staff hourly costs, the CRO will charge a benefit margin to the client. In general, efforts are calculated by an FTE index (Full time equivalent), meaning 1 FTE a 100% dedication of one person to a certain task. For example, one data manager working half the time for one month would be 0.5 FTE. CROs may also include in their proposal specific services subcontracted to other vendors. In these cases, the price given by the CRO to the final client would be based on the price provided by the subcontracted vendor plus some benefit margin. "
Ex-TR1 (ex-banker), holder classed this share as trade opportunity btw 8-10 then downgraded his trade opportunity btw 6-8 some months ago. The prof got himself advisory position with the company. some say sold the rest of investors.
valirx got:
* val series repurposed compound dusting on shelf after so many years & so many mil ยฃ spent ( noncommercial ), golden one is val201 with 11 indications & 54.4% respond rate (average respond rate 44%), no established pharma showed any interest as we know of
* clx001 licensed almost a year ago, no one knows at what stage since then
* lab in collaboration with another failing aim company
* biobank
some expects a fund raise btw 2.25-5 in q4 & others say got money into 2024. ( 01/01/2024 means we are into 2024).
current ceo was put there with the same investors who now wants her out but cant do it without the profs notes.
all depend on ones appetite for R:R ratio & @ what time frame
Many wish it was for Synergia. will it be in near future? will fomo kick in bottom-pickers ?
https://twitter.com/MEIL_Group/status/1686957564381339648
does addition of this man to DGH have any ramifications for synergia?
https://twitter.com/ET_Government/status/1689192465134407680
Once your in dry cleaner, they first empty your pockets, dont blame the dry cleaner for doing their job.
just remember WHO guided you to dry cleaner at first place. As you travel to dry cleaner, a lot of water gone under the bridge, but followed their guidance anyway with a hopium. Them shameless still at it.
First revenue invoiced ๐, however them expected future contracts wont save the a$$ of Valirx. The prof, exbanker & spoons saved theirs already.
The new molecule targets a protein present in most cancers that helps tumors grow and multiply in the body.
It is significant because this protein - the proliferating cell nuclear antigen (PCNA) - was previously thought to be 'undruggable'.
The drug was tested on 70 different cancer cells in the lab - including those derived from breast, prostate, brain, ovarian, cervical, skin, and lung cancer - and was effective against them all.
The drug is currently being tested on humans in a Phase 1 clinical trial at City of Hope.
By Caitlin Tilley Updated: 01:42, 2 August 2023
Any progress on clx, influencers do your bit
British billionaire Joe Lewis has been charged with orchestrating an insider trading scheme in which he allegedly tipped off friends and associates so that they can profit off of stock trades in several #biotech companies. https://twitter.com/endpts
Witnessed an investor, in Synairgen #SNG holding 700,000 shares valued @ ยฃ1,200,000 the day before results, had to sell all for just over ยฃ100,000 on result day.
Hopium fed by members/admin of private social media groups, members/admin of ADVFN Guilds & including experts on LSE and also self inflicted greed made him not to sell earlier, despite numerous warnings.
Some one said here before that hope + greed are killing it.
Seen greed here in #VAL, also been witnessing Hopium fed day-in day-out.
some one knows this very well: Each to their own
Sentiment here killed by the arrival of RNS Number : 2793E, then a week later with the request of Directorate of Hydrocarbons ("DGH"). Request of DGH gives a way to assumption of them being potential JV partner , Minister Puri said " You don't even need to spend your own money. If you have the expertise, we are willing to incentivise it."
Zaks tweet had 1,266 views mainly investors, Synergias tweet had 2,638 views investors & industry, so safe to say that a lot of sitting on the sideline and waiting a few things got clarified.
CEO talking about mcap of company opens up lid of jar, triggering a question of possible ..... that also kills the sentiment. Never seen a ceo saying mcap of the given company too high, Roland jinxed it.
imho
Wonder if Roland, Synergia, showed interest on this;
Minister Puri said, "You need to make data available, and you need a change in the mindset. Earlier, people would not come for exploration. Now, we are incentivising exploration. You don't even need to spend your own money. If you have the expertise, we are willing to incentivise it."
https://www.moneycontrol.com/europe/?url=https://www.moneycontrol.com/news/business/with-survey-completed-in-andamans-india-may-now-proceed-with-oil-exploration-10784701.html